Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 12, Pages 777-786Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41571-018-0102-3
Keywords
-
Categories
Funding
- Centers for Disease Control and Prevention
- NIH/National Cancer Institute
- American Association for Cancer Research
- American Cancer Society
- American College of Radiology
- ASCO
- American Society of Hematology
- Association of American Cancer Institutes
- Bristol-Myers Squibb
- Cancer Support Community
- CEO Roundtable on Cancer
- Flatiron Health
- Helsinn Therapeutics (US)
- LIVESTRONG Foundation
- Merck
- National Comprehensive Cancer Network
- Novartis Oncology
- Oncology Nursing Society
- Pfizer
Ask authors/readers for more resources
The traditional approach to drug development in oncology, with discrete phases of clinical testing, is becoming untenable owing to expansion of the precision medicine paradigm, whereby patients are stratified into multiple subgroups according to the underlying cancer biology. Seamless approaches to drug development in oncology hold great promise of accelerating the accessibility of novel therapeutic agents to the public but are also accompanied by important trade-offs, including the limited availability of information on the clinical benefit and safety of novel agents at the time of market entry. In this Perspectives article, we describe several opportunities, in the form of novel trial designs or modelling strategies, to improve the efficiency of drug development in oncology, as well as new mechanisms to obtain information about anticancer therapies throughout their life cycle, such as innovative functional imaging techniques or the use of real-world clinical data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available